The Basel-based partner to the pharmaceutical industry has set up the new QC division to support release and stability testing of clinical and commercial sterile drug products according to international cGMP standards
ten23 health has announced the launch of quality control (QC) service offerings in Switzerland for release and stability testing of clinical and commercial sterile drug products according to international cGMP standards.
The new quality control division will be set up at two locations of ten23 to cater to diverse testing requirements and to best align with our other offerings on each site.
In Basel ten23 health will offer physico-chemical testing, including content, purity, identity and pharmacopeial methods to ensure the release and stability of sterile, pharmaceutical Drug Products for clinical and commercial use. These services will be integrated with the pharmaceutical development service provided by ten23 in Basel.
The company provides microbiological quality control services, encompassing environment monitoring and final product microbiological testing, including sterility
In Visp, the company provides microbiological quality control services, encompassing environment monitoring and final product microbiological testing, including sterility. The microbiological services in Visp will be co-located with our operations of our sterile product manufacturing and where we are currently underway with the expansion, constructing further sterile filling capacity.
ten23 already has hired experts into critical roles for our QC services, and these new service offerings will also bring additional potential for future jobs in both the Basel and Visp regions. We expect to be operational and GMP ready for our quality control services by Q2/2024.
We aim to streamline the development, testing and manufacturing processes for our clients, enabling them to focus on their core competencies
- Hanns-Christian Mahler, CEO of ten23 health
The introduction of quality control services complements ten23’s existing offerings, making it an ideal partner for pharmaceutical companies throughout the product life cycle. Clients can now benefit from the seamless integration of services that cover development, manufacturing and testing.
This includes our offerings for formulation development, DP process development, analytical method development, packaging and device selection support and integration, special testing for Particulates and Container Closure Integrity, stability testing, GMP fill & finish and GMP release and stability testing.
This strategic move further solidifies ten23’s commitment to delivering comprehensive and high-quality services to its esteemed clients & partners. By offering a range of testing capabilities ten23 will become an integrated solution provider for pharmaceutical companies seeking reliable and efficient pharmaceutical supply chain solutions for sterile drug products, supporting the development and commercialisation of safe, effective and well-differentiated sterile products for the benefit of our customers' patients.
“We are excited to announce the expansion and the launch of our quality control services,” said Hanns-Christian Mahler, CEO of ten23 health. “By adding these services, we aim to streamline the development, testing and manufacturing processes for our clients, enabling them to focus on their core competencies while we can handle their needs for pharmaceutical development, sterile manufacturing and testing.”